US Patent 7811767 Methods and compositions for assessing acute rejection
Patent 7811767 was granted and assigned to Novartis on October, 2010 by the United States Patent and Trademark Office.
All edits
Edits on 14 Aug, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 31 Oct, 2023
Golden AI
Edits made to:
Article (+257 characters)
Article
Patent abstract
The invention relates to the analysis and identification of genes that are up-regulated simultaneously in transplant rejection. This simultaneous up-regulation of genes provides a molecular signature to accurately detect transplant rejection.
Edits on 18 Sep, 2023
Golden AI
Edits made to:
Infobox (+3 properties)
Infobox
Patent Inventor Names
Friedrich Raulf0
Hai Zhang0
Pierre Saint-Mezard0
Edits on 23 May, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 07811767 Methods and compositions for assessing acute rejection US Patent 7811767 Methods and compositions for assessing acute rejection
Infobox
Patent Number
078117670
Patent Number
78117670
Edits on 21 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 5 Apr, 2023
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
078117670
Date of Patent
October 12, 2010
0Patent Application Number
122820290
Date Filed
March 13, 2007
0Official Website
Patent Primary Examiner
Edits on 3 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 6 Dec, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 07811767 Methods and compositions for assessing acute rejection
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
07811767
Date of patent
October 12, 2010
Patent application number
12282029
Date Filed
March 13, 2007
Patent primary examiner
Find more entities like US Patent 7811767 Methods and compositions for assessing acute rejection
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.